March 09, 2026 — 9 articles reviewed
This cycle’s headlines split sharply between cardiovascular risk signals from cannabis use and developments that strengthen the case for regulated, evidence-based cannabis medicine. Clinicians will find actionable updates on stroke counseling, veteran access advocacy, analytical chemistry advances, and cognitive safety data in older populations.
This batch of news captures the central tension in cannabis medicine right now: we have real cardiovascular risks that demand honest patient counseling alongside mounting evidence that regulated, well-characterized cannabis products can serve populations our conventional tools have failed. The path forward is not prohibition or permissiveness but precision, and that requires better data, better products, and better conversations with every patient.